AxisBiotix, a subsidiary of SkinBioTherapeutics, has reported positive feedback from its food supplement consumer study on its acne formulation.
The study
The 8-week consumer volunteer study explored what 98 participants thought of AxisBiotix’s food supplement blend, AxisBiotix Acne.
The supplement containing the lead formulation was supplied to participants in powder form, and participants were asked to record scores against specific criteria on an app.
The scoring criteria incorporated:
- Severity of acne
- Level of pain associated with acne
- Attitude to appearance
- Confidence levels
The results
From analysis of the data collated in this study, AxisBiotix report that 84% of participants had experienced a reduction of the appearance of their spots, 77% had reduced pain caused by their acne, 62% had reduced anxiety relating to their spots and 58% had felt there was positive impacts on their social lives from taking the supplement.
Of the 91 participants that completed the exit survey (93% of participants), 89% reported that they would continue using the supplement and recommend it to others.
CEO of SkinBioTherapeutics, Stuart Ashman said: “The results of the study stand as a testimonial to the effectiveness of our AxisBiotix Acne food supplement technology in treating acne skin conditions. Now, our attention turns to planning the commercialisation of the product to a market eager for effective solutions. We still have some work to do on end formulation but our focus is very much on commercialisation. This second food supplement greatly de-risks the science when discussing wider launches with larger, multinational partners.”
